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Inhibitors of mitochondrial branched chain aminotransferase (BCATm), identified using 
fragment screening, are described.  This was carried out using a combination of STD$NMR, 
thermal melt (Tm) and biochemical assays to identify compounds that bound to BCATm, which 
were subsequently progressed to X$ray crystallography, where a number of exemplars showed 
significant diversity in their binding modes. The hits identified were supplemented by searching 
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and screening of additional analogues, which enabled the gathering of further X$ray data where 
the original hits had not produced liganded structures. The fragment hits were optimised using 
structure$based design, with some transfer of information between series, which enabled the 
identification of ligand efficient lead molecules with micromolar levels of inhibition, cellular 
activity, and good solubility.  
 	
Mitochondrial branched chain aminotransferase (BCATm) is a metabolic enzyme which 
converts the branched chain amino acids (BCAAs), leucine, isoleucine and valine into their 
corresponding α$keto acids. Over the past few years, evidence has appeared linking this enzyme 
to obesity in animals and humans; accordingly inhibition of this enzyme has potential as a 
treatment for obesity and related diseases. The BCATm isoform is expressed ubiquitously, with 
very high levels in the stomach, pancreas and salivary glands, consistent with its role in protein 
metabolism.1 Interestingly, BCATm knock$out mice are resistant to high$fat diet induced obesity 
and diabetes;2 these effects are believed to be caused by the establishment of an energy 
consuming cycle of protein synthesis and degradation. This phenotype is similar to that observed 
in humans who consume high protein diets or BCAA supplements and experience increased 
energy expenditure, lower appetite and ultimately, lower body weights.2 The role of BCATm and 
BCAAs in the aetiology of obesity is complex and not fully understood; knock$out and dietary 
studies discussed above, where high levels of BCAA appear to be associated with reduced risk of 
becoming obese, are complicated by studies of obese animals. Genetically mutated obese rodents 
and diet$induced obese mice and humans have all been shown to have reduced BCATm 
expression, resulting in higher BCAA levels than lean animals.3 
Page 2 of 60
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 3
The search for inhibitors of BCATm at GSK was pursued using three complementary methods; 
fragment screening, high throughput screening (HTS) and encoded library technology.  This 
paper describes the diversity of chemical matter, displaying distinct binding modes discovered 
by fragment screening.  Hybridization of one of these hits with an HTS hit led to a potent 		 
active series4 and a further series was identified by encoded library technology.5 Together, this 
package of work has shed much light on the variable binding modes observed with BCATm and 
is beginning to shed some light on the effects of specific pharmacological inhibition of BCATm 
by small molecules and the role of this enzyme in disease.   
In a commentary6 on our Fragment Assisted Drug Design7 paper, the difficulty of the target 
was highlighted, as was the importance of having diverse chemical matter with appropriate 	
	 activities to interrogate a target; this paper illustrates structural information describing 
diverse binding modes observed.  In fragment screening, the lack of overlap between screening 
methods has been acknowledged8; this was observed in the progression of hits identified by the 
various methods in this fragment screen, perhaps compounded by the diversity of binding modes. 
  The fragment hits were clustered according to their distinct binding modes. Importantly, this 
study provides new structural understanding of this enzyme, with several binding pockets 
identified by the fragment screen, which were not occupied by either of the other series4,5. 
Additionally, further optimisation efforts on two of the fragment hit series are described, which 
represent useful starting points and give important structural pointers to enable the identification 
of structurally novel tools for further pharmacological studies.  
#		
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FBDD techniques have become an integral part of the drug discovery process during the last 
decade.7910 Standard components of the FBDD methodology include the use of biophysical 
screening and X$ray crystallography to enable the identification, optimisation and designed 
growth of inherently weakly binding ligands into potent lead molecules.11  Commonly, these 
methods have used a single form of the protein, for example, the apo or a cofactor bound state.  
However, during enzyme turnover in solution, the dynamic changes in protein conformation 
and biochemical state present a number of potential binding opportunities. The use of a single 
form for screening in a binding assay may restrict the type of compounds that can be detected 
and characterised.  In the extreme case, this arbitrary choice may preclude sampling the most 
tractable form of the enzyme. During the catalytic cycle (Scheme 1) PLP and PMP cofactor 
bound forms of BCATm are sampled. Pragmatically we therefore used both PLP and PMP forms 
in our studies where possible, as these can both be stably isolated. 
At the start of the cycle, the cofactor pyridoxal phosphate (PLP) is covalently bound to the 
enzyme 	 a lysine residue (Lys$202) (Scheme 1).12  This lysine is then displaced by the α$
amine of an incoming BCAA substrate. The imine formed is hydrolysed to the corresponding α$
keto acid. In the course of the reaction, the co$factor is released from its covalent bond to the 
enzyme as pyridoxamine phosphate (PMP). A complementary half$reaction occurs to complete 
the cycle, whereby α$ketoglutarate is transaminated to glutamate and the PLP form of the 
enzyme is regenerated. It was possible to characterise both the PLP and PMP forms of the 
enzyme (e.g. spectroscopically or by mass spectrometry) and to interconvert between these using 
an excess of either leucine or α$keto glutarate as appropriate. 
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A functional biochemical assay was designed to detect inhibitors of this pathway, making use 
of a coupled sequence of enzymes (Figure	$), whereby the glutamate product of BCATm activity 
was re$oxidised to α$keto glutarate along with hydrogen peroxide by the enzyme glutamate 
oxidase. The peroxide thus generated was detected by reaction with 1$(3,7$dihydroxy$10H$
phenoxazin$10$yl)ethanone to form resorufin, catalysed by the enzyme horseradish peroxidase. 
Decoupled parallel control wells, without the BCATm initiated step were added to detect any 
inhibitors of the coupled processes. A potential risk of carrying out fragment screening using 
such a coupled enzyme system was that genuine inhibitors of BCATm could be discarded as 
non$specific in nature due the higher chances of fragments interacting with more than one 
Page 5 of 60
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 6
enzyme. Theoretical reasoning based on complexity,13 on which much of FBDD methodology is 
predicated, suggest that there is a higher probability of smaller molecules binding to any given 
protein than for larger molecules. Therefore, it is more likely that fragments binding to BCATm 
may also bind to the coupled enzyme glutamate oxidase than would be the case if this assay was 
used for a traditional HTS campaign with larger, more complex molecules. However, using this 
functional biochemical assay had the advantage that all biochemical forms of the protein 
necessary for reaction could be sampled, permitting the detection of inhibitors that inhibited only 
one of these forms. 
 
"	$%				
As is common in fragment screening campaigns, complementary biophysical screening was 
also carried out to detect compounds which bound to BCATm; in this case NMR and thermal 
shift techniques were used. The saturation transfer difference (STD) NMR assay14 used a mixture 
of the PLP and PMP forms of the enzyme. Hits identified may interact with either, or potentially 
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both, the PLP and PMP forms of the protein. However, as both forms are catalytically relevant 
the precise binding profile was not initially determined as all hits had the potential to yield 
functional inhibitors. The STD$NMR approach was complemented by a thermal shift screen 
(Tm),
15 where both forms of the enzyme were independently assayed. This was necessary 
because of the very different denaturation temperatures of the PLP(E) and PMP(F) bound 
proteins, 73 °C and 54 °C, respectively. 
The GSK core fragment library of 1056 compounds was screened in parallel through all three 
assays and hit rates are shown in " &. The crystallography was carried out by soaking high 
concentration solutions (40 $ 60 mM) of the ligand of interest into preformed crystals of both 
PMP and PLP forms of the protein for one to fourteen days, sometimes yielding liganded crystals 
that gave datasets sufficient to unambiguously determine binding modes (resolutions in the range 
1.8 $ 2.4 Å). Although crystals of both the PLP and PMP forms of the BCATm were tried, the 
initial hits only yielded complexes with the more stable PLP protein. We therefore took the 
pragmatic decision to prioritise inhibitors for which crystal structures could be elucidated, 
thereby concentrating efforts on inhibitors of the PLP form of BCATm.  	
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The output of the fragment screening is summarised in Figure 2. The different screening 
techniques produced different sets of hits, which is a common observation in FBDD campaigns8, 
as screening is carried out close to the limits of detection for the assays and different 
experimental conditions may favour a particular target conformation. All of the hits from either 
of the biophysical assays were progressed to X$ray crystallography. The STD$NMR experiment 
gave the better success rate in identifying apparent binders that led to liganded X$ray structures, 
with the orthogonal thermal shift experiment showing a relatively poor prediction of success. 
The biochemical assay had yielded a high number of specific hits, which could not all be 
progressed to crystallography, so the STD$NMR data was used to triage these hits, using a lower 
cut$off (2 × signal to noise, versus 4 × signal to noise) than was used in the initial selection of 
NMR hits.  
Additional activities were carried out in an effort to increase the number of liganded X$ray 
structures as potential starting points for chemical optimisation. Five compounds identified were 
hits in both Tm and NMR assays but failed to produce crystal structures. Given reasonable 
confidence that these compounds were genuinely binding to BCATm, structural analogues were 
sourced from the GSK compound collection and screened in the STD$NMR and biochemical 
assays. Analogue searching was performed by focussed substructure searching complemented by 
a GSK$developed workflow, 0	(, specifically designed for fragment follow$up. 
0	( combines substructure and similarity searching methods with different 
descriptors and constraints on compound properties to identify suitable fragment like analogues 
from both in$house and external vendors (see Experimental for details). 80 compounds were 
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selected from this exercise and screened. 32 compounds were identified with activity in one of 
the two assays, from which three yielded liganded structures where the original fragment hit had 
not ($&)	$.)	$/). An additional 120 similarly selected analogues were subsequently screened and 
yielded valuable SAR for compounds 0 and / as described below. 
Concurrent with this fragment screen, a high throughput screen of the GSK HTS compound 
collection (1.7 million compounds) had been conducted. The single$shot percentage inhibition 
data and subsequent XC50 data were interrogated for compounds that were identified by the 
0	( search. Four analogues of $	were identified with micromolar activity in the HTS 
and were submitted to crystallography, yielding additional liganded structures 1 and $2.  
	 	
Page 10 of 60
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 11
"	3 
(	
4!	
	 ( /2	 5	
3	
	
6	 6	 	 		
$	
 
 
<2.9 0.78 13 
  
STD$NMR  
PLP lipophilic pocket, 
Hydrogen bond acceptor 
to Ala$314 
&	
 
 
<2.9 1.25 15 
  
Tm and 
STD$NMR 
PLP lipophilic pocket, 
Hydrogen bond acceptor 
to Ala$314 
.	
 
 
<2.9 1.57 15 
  
STD$NMR 
PLP lipophilic pocket, 
Hydrogen bond acceptor 
to Ala$314 
0	
 
 
4.2a 0.62 15 0.38 0.43 
STD$NMR 
and 
biochemical 
π$ stacking to Phe$30, 
Hydrogen bond acceptor 
to Lys$79 
/	
 
 
3.0b 1.31 15 0.27 0.26 
STD$NMR 
and 
biochemical 
π$ stacking to Phe$30,  
PLP lipophilic pocket 
7	
  
<2.9 1.96 11 
  
STD$NMR 
Interface between 
protein dimers (no 
functional effect) 
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8	
  
3.1 $0.2 13 0.33 0.45 
STD$NMR 
and 
biochemical 
PLP lipophilic pocket, 
Hydrogen bond acceptor 
to Ala$314,  
Displacement of water 
adjacent to Cys$315 
9	
 
 
3.9 1.6 14 0.38 0.33 
STD$NMR 
and 
biochemical 
π$ stacking to Phe$30,  
PLP lipophilic pocket 
1	
 
 
6.6 3.8 18 0.48 0.30 
HTS hit with 
similarity to 
fragment 
hits 
Hydrogen bond acceptor 
to Ala$314 
$2	
 
 
5.1 2.69 18 0.39 0.29 
HTS hit with 
similarity to 
fragment 
hits 
π$ stacking to Phe$30 
$$	
 
 
3.3c 0.21 16 0.28 0.41 
Tm, STD$
NMR and 
biochemical 
No crystal structure 
obtained 
$&	
 
 
<3.2
d 
0.14 15 0.40 0.50 
Analogue of 
$$ 
PLP lipophilic pocket, 
Displacement of water 
adjacent to Cys$315 
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$.	
 
 
4.6 0.77 19 0.44 0.45 
Analogue of 
$$ 
PLP lipophilic pocket, 
Displacement of water 
adjacent to Cys$315 
$0	
 
 
3.8 1.9 14 0.37 0.29 
Tm, STD$
NMR and 
biochemical 
No crystal structure 
obtained 
$/	
 
 
3.8 2.08 15 0.35 0.26 
Analogue of 
$0 
PLP lipophilic pocket, 
Hydrogen bond acceptor 
to Ala$314 
 !	$					-	a compound reported inactive (pIC50 < 4.2) on 3  
out of 35 test occasions; b compound reported inactive (pIC50 < 2.9) on 1 out of 2 test occasions; 
c compound reported inactive (pIC50 < 2.9) on 1 out of 3 test occasions; 
d compound reported 
inactive (pIC50 < 3.2) on 2 out of 4 test occasions.	
!	$ summarises the fragment hits identified which yielded liganded crystal structures, along 
with their calculated ligand efficiency (LE)16 and modified lipophilic ligand efficiency (LLEAT) 
as defined by researchers at Astex.17 The crystal structures obtained for the hits, showed 
occupation of a range of positions in the BCATm binding site, and that significant movement in 
the protein was induced by the compounds. Some of the most important features for binding are 
summarised in the X$ray crystal structures shown in "	.. 
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Benzo[]isoxazole $	("	.) occupied a binding pocket defined by a lipophilic region 
adjacent to the PLP cofactor, which is confined by a closed ‘gate’ between residues Phe$30 and 
Tyr$173. The carboxylic acid carbonyl group acted as a hydrogen bond acceptor to the backbone 
NH of Ala$314. 
The crystal structure of thienopyrimidine 0	("	.!) 	showed occupation of a distinct 
binding site. The site adjacent to the cofactor was occupied only by ethylene glycol (present in 
crystallography medium) and the Phe$30 Tyr$173 ‘gate’ had opened to allow the formation of a 
π$stacking interaction between Phe$30 and the heterocyclic core. The opening of the gate 
involved significant conformational rearrangement, with Phe$30 moving by around 2 Å, whilst 
Tyr$173 moved by approximately 6 Å. Additionally, the amide carbonyl acted as a hydrogen 
bond acceptor to a lysine NH (Lys$79). 
The pyrimidine ring of the biaryl amide / ("	.) formed a similar π$stacking interaction 
with Phe$30 to thienopyrimidine 0, whilst the phenyl ring occupied a similar lipophilic aromatic 
pocket to benzo[d]isoxazole $. The tyrosine residue, which moved to open the induced pocket in 
the structure of 0 (Tyr$173) was completely disordered in this structure. There are no direct 
hydrogen bonding interactions between the heteroatoms of the fragment and the protein, which 
may explain the poor ligand efficiency observed. However the amide carbonyl is well solvated 
and there is a water mediated hydrogen bond to the hydroxyl of Tyr$141. Biaryl amide / was an 
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effective bridge between the two binding sites identified, and demonstrated that it is possible to 
have both sites occupied simultaneously. 
Pyrazolopyrimidine $&	("	.	PDB entry 5BWT4) displayed an additional distinct binding 
mode. The pendant ethyl group was close to the lipophilic site occupied by aromatic groups for 
compounds $ and /)	and the ‘gate’ was closed.  The heterocyclic core was positioned in a site 
which was unoccupied in the other structures, with the nitrile substituent displacing a water 
molecule, which formed a hydrogen bonding interaction with the NH of Cys$315 in other 
structures. The pyridone carbonyl forms hydrogen bonds with Tyr$173 and the backbone of Val$
155. The pyridone NH and pyrazole N are both involved in water networks. 
When all of these liganded crystal structures of the fragment hits were considered together 
("	. and ), it was clear that the BCATm protein has considerable flexibility to 
accommodate a range of ligand binding modes. However, there were several binding ‘hot$spots’ 
identified, which appeared to act as anchors for the fragments. The most notable of these was the 
lipophilic pocket adjacent to the PLP, hydrogen bonding with Ala$314, π$stacking with Phe$30 
and displacement of the water molecule adjacent to Cys$315. All of the hits identified satisfied at 
least one of these interactions (see !	$). This flexibility in the protein would thus have 
caused difficulties in attempting to predict the binding modes of hits using docking methods 
alone. Therefore, to enable structure based fragment growth, it was important to generate 
multiple X$ray crystal structures (as is common practice), even for compounds which appeared 
to be closely structurally related.  The diversity of structural information obtained provided 
opportunities to grow the fragment hits in various ways18. 
3			;(	
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The fragment hits identified were grouped (“clustered”) according to their binding modes in 
the BCATm active site. An example of this process is shown for compounds $, &	and ., which 
look dissimilar on the basis of their chemical structures, but which all make similar binding 
interactions with the protein ("	0). One exemplar was chosen from each vectorial cluster, 
either because it demonstrated superior efficiency of binding, or because it offered more flexible 
and tractable chemistry than other structures within the same cluster.  The fragment growth and 
further optimisation of the pyrazolopyrimidinone series represented by compounds $$,$. is 
described in the complementary paper; 4 a noteworthy feature of this series was that the original 
fragment hit ($$) did not give a crystal structure, but analogue searching identified closely 
related compounds that did yield liganded crystal structures. Herein, the initial lead optimisation 
efforts on two other series to illustrate the strategies employed are described. 
  
"	0%	6<(			)	'				(	$		5
	
 / /)	 &	5
	 / /		.!	5
	 / /=	'	 	!	
- 
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Thienopyrimidine 0 had very favourable LE and LLEAT values and contained a tractable 
functional group (carboxylic acid), which could be used to grow towards the PLP pocket. The 
crystal structure of biaryl amide /	provided further confidence in this approach because it 
showed that concomitant binding in both of these pockets could be achieved. With these aims in 
mind, initial optimisation focussed on a small array of amides, mostly containing lipophilic 
substituents, which were designed to fill the PLP pocket. 
These compounds were synthesised using HATU$mediated coupling chemistry or 	 acylation 
using the appropriate acid chloride (!	&). Due to monomer availability, some of the 
chemistry was carried out on the closely related des$methyl series e.g. $7, which showed similar 
activity to the initial hit 0. Analogues $8	and $9	confirmed that activity with either of these two 
substituents was comparable. In general, aromatic amides were preferred to aliphatic 
substituents, as demonstrated by the comparisons between compounds $8	and $9	plus $1	and &2. 
Substitution on the pendant phenyl ring was only tolerated in the 
 position (compounds &$, 
&&, &.). Attempts to accommodate heteroaromatic rings in the lipophilic pocket were not 
productive (e.g. compounds &0	and &/), with the exceptions of the lipophilic thiophene (&7) and 
thiadiazole (&8), both of which also maintained the highly favourable LE and LLEAT values of 
the hit.  
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"	/%	;		(	&8	((	5
	 / /+		&1	(		5
	 
/ />-	5	-	'				'	,81)	5,.2		,.$0-	5	!-	
						55?55			'	( 
The potency associated with compound &8	could not be rationalised by knowledge of the 
crystal structure of compound 0. Soaking experiments failed to produce a crystal structure of 
compound &8, however co$crystallisation was successful, which yielded the first liganded 
structure of BCATm in the PMP form ("	/). The PMP form shows a few significant 
differences with respect to the PLP form. Firstly, the Lys$202 sidechain, now no longer 
covalently linked to cofactor, as in the PLP form, is free to shift slightly to optimally interact 
with one of the nitrogen atoms in the thiadiazole ring. Secondly, the PMP cofactor pyridine 
rotates by ~11° from the PLP pyridine plane and Leu$266 adopts a lower energy rotamer 
conformation due to the additional space created by the rotation of the PMP pyridine ring.  Due 
to its potent inhibition of BCATm, compound &8 was progressed to a cellular assay measuring 
BCATm inhibition, and was found to have a cellular pIC50 value of 5.4.  
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Compound 
Number 
R1 R2 pIC/2  LE  LLE  
0	
	
CH3 OH 4.2
a 0.38 0.44 
$7 
 
H OH 4.3 0.44 0.51 
$8		
	
CH3 
 
5.1 0.33 0.34 
$9	
 
H 
 
5.1 0.36 0.37 
$1  
 
CH3 
 
< 4.2  
&2		
	
CH3 
 
< 3.2 
&$	
 
H 
 
4.3b 0.28 0.30 
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&&	
 
H 
 
< 4.2 
  
&.	
 
H 
 
< 4.2 
  
&0	
 
H 
 
3.6 0.25 0.33 
&/	
 
H 
 
< 4.2  
  
&7	
 
H 
 
5.8 0.48 0.45 
&8	
 
H 
 
6.7 0.48 0.63 
	
!	&%									(	0- 
a compound reported inactive (pIC50 < 4.2) on 3 out of 35 test occasions; 
b compound reported 
inactive (pIC50 < 4.2) on 2 out of 4 test occasions. 
The next logical expansion was to grow towards Ala$314 to try to exploit a hydrogen$bonding 
opportunity, which had been identified from the fragment screening as a binding hot$spot. A 
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range of heteroatom$containing functional groups were introduced in the 
$position of 
compound $9	(!	). From this effort, only the aryl acetate &1 showed any significant 
improvement in BCATm inhibition resulting in micromolar activity, whilst maintaining good 
efficiencies. Crystallisation of this compound in BCATm ("	/)  confirmed that the acid 
carbonyl moiety was acting as a hydrogen bond acceptor to the backbone NH of Ala$314. 
 
Compound 
Number 
R pIC/2  LE  LLE  
$9	
 
H 5.1 0.36 0.37 
&9	
  
< 4.2 
  
&1	
  
6.0 0.34 0.45 
.2	
 
 5.0 0.31 0.44 
.$	  
4.9 0.28 0.41 
Page 22 of 60
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 23
 
.&	
  
< 4.2 
  
 
!	.%	#			,.$0		'		,(		$9	
By using the structural information obtained from different fragment hits to identify binding hot 
spots it was thus possible to grow weakly active fragment 0	into more potent analogues, with 
activity in a cellular assay.  
Analysis of structures showed that biaryl amide / offered potential vectors towards the Ala$
314 NH donor and the Lys$79 NH2 donor, to which the pyrimidinone carbonyl of 0 was 
hydrogen bonded. The biaryl amide substructure is an abundant motif in the GSK compound 
collection, so the initial SAR was readily delineated (!	0).  
Compound  Structure pIC50 LE LLEAT clogP 
/	
 
 
3.0 0.27 0.26 1.31 
..	
 
 
< 3.2 
  
2.65 
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.0	
 
 
3.7 0.27 0.26 1.66 
./	
 
 
3.5a 0.25 0.25 1.58 
.7	
 
 
5.6 0.39 0.31 2.86 
.8	
 
 
5.3 0.36 0.26 3.00 
.9 
 
 
5.7 0.33 0.32 1.94 
 
!	0%						5	!			@A	.   
a compound reported inactive (pIC50 < 4.2) on 2 out of 4 test occasions. 
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The pyrimidine ring was initially replaced with phenyl, as a greater number of analogues were 
available, and the crystal structure of / suggested that the pyrimidine nitrogens were not 
participating in any binding interactions. As with the optimisation of 0, it was found that adding 
hydrogen bond acceptors, which could interact with Ala$314, provided modest improvements in 
binding (.0 and ./), with maintained ligand efficiency. A more dramatic improvement in 
enzyme inhibition was achieved when hydrogen bond acceptors, represented by carboxamide 
and pyrazole (.7 and .8), enabled engagement with Lys$79. Carboxamide .7 also had additional 
lipophilic chlorine groups that enhanced binding in the PLP pocket, contributing to micromolar 
levels of activity, which represented a roughly 1000$fold increase in activity from the fragment 
hit. This compound also displayed a significant improvement in the efficiency measures relative 
to the hit compound /.  Synthesis of compound .9, which combined the acceptors targeting both 
Lys$79 and Ala$314 demonstrated that the effects on the activity could be additive, with good LE 
and LLEAT values achieved. The intent of this design was confirmed by the Xray structure of .9 
within BCATm shown in "	7.  
 
"	7%	;		(	.9	!	5
	 / 72		/	(:	5
	 / /	
	.9	:			'	,81		,.$0-	
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Once a good understanding of the SAR within this series had been established through 
screening of available analogues, attention was turned to improving the physicochemical profiles 
of the compounds. Biaryl amides are notoriously insoluble, being highly planar and crystalline,19 
and indeed, the measured solubilities of these compounds were poor (!	, compounds .8 and 
.1). Two strategies were adopted to improve the solubility within the series. The amide N$H was 
constrained in a tetrahydroisoquinoline ring to prevent intermolecular hydrogen bonding, which 
could contribute to the high crystallinity (02 and 0&). Additionally, the pyrimidine ring from the 
initial hit was returned to the molecules in place of the phenyl ring to lower the lipophilicity 
(compound 0$). The targeted analogues were synthesised as shown in 	&. Both of these 
strategies resulted in a modest improvement in enzyme inhibition and approximately 10$fold 
increased solubility. As in the optimisation of thienopyrimidine 0, the biaryl amide series had 
been grown into a series of lead$like molecules through focussed structure$based design 
combined with consideration of molecular properties.  
Compound  Structure pIC50 LE LLEAT clogP Sol(µg/ml) 
.1	
 
 
4.3a 0.33 0.33 1.46 13 
02	
 
 
4.8 0.33 0.36 1.14 132 
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.8	
 
 
5.2 0.36 0.26 3.00 12 
0$	
 
 
5.5 0.38 0.35 1.94 82 
0&	
 
 
5.8 0.36 0.29 2.83 94 
 
!	/%	
			!		)				
		(	!-	
a compound reported inactive (pIC50 < 4.2) on 1 out of 4 test 
occasions 
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Reagents and conditions: (a) HATU, DIPEA, DMF, 20 – 40 °C, 41$79 %; (b) 1$pyrazol$3$
ylboronic acid, Pd(PPh3)4, Na2CO3 (sat. aq.), 130 °C, microwave 20 min. 41 – 72 %; (c) CuI, 
K2CO3, DMF, 160 °C, 18 h, 57 – 66%; (d) 2M NaOH (aq.), 30 % H2O2 (aq.), EtOH, 50 °C, 20 h, 
19 %. 
	&%					(	/	
	
When carrying out any diversity screening campaign, but particularly when utilising fragment$
based approaches, it is important to realise that different biochemical and biophysical screening 
techniques can, and indeed do, identify different sub$sets of hits. Therefore, there could be an 
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advantage to using multiple, complementary techniques for the initial screening phase. This is 
particularly important in FBDD, where the binding of hits will likely to be near to the limit of 
detection in some assays.  This set of hits identified for BCATm, and the crystal structures 
generated have illustrated many aspects of the binding of small molecules to this enzyme for the 
first time. It was particularly interesting to observe such different conformations of the protein 
between different fragment hits, whilst gratifying to be able to identify several binding ‘hot 
spots’ in the protein structure and confirm that these could be accessed simultaneously and from 
different structural types. The insights from multiple liganded crystal structures during both the 
screening and chemical optimisation stages were invaluable in guiding progress, consistent with 
contemporary practice1120 in fragment based design.  Another important aspect of this work was 
the use of analogue searching from an extensive collection. This was important both in the hit 
finding phase, where it was used to generate additional hits, and in fragment optimisation and 
growth, where significant improvements in hit activities were obtained without recourse to 
synthesis. The chemical libraries are a major asset for large pharmaceutical companies, which 
allow scientists to rapidly explore SAR around fragment hits. The “SAR by catalogue” allowed 
expansion beyond the deliberately designed screening sets, whilst continuing to exercise 
discipline with the molecular properties of compounds screened. Finally, micromolar inhibitors 
of BCATm have been identified, with characterised novel binding modes and measurable 
activities in a cellular assay. This represents a major step forward towards the goal of 
establishing if pharmaceutical inhibition of BCATm using small molecules could provide a 
useful treatment for metabolic diseases; the accompanying paper4 describes further progress 
achieved in one series. 
6<(	
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	
All solvents and reagents, unless otherwise stated, were commercially available from regular 
suppliers such as Sigma$Aldrich and Fluorochem and were used as purchased without further 
purification. Nuclear magnetic resonance (1H NMR and 13C NMR) spectra were recorded on a 
Bruker AVI (400 MHz), Bruker Nano (500 MHz) or Bruker AVII+ (600 MHz) spectrometer 
(with cryoprobe) in the indicated solvent. Chemical shifts δ are reported in parts per million 
(ppm) relative to tetramethylsilane and are internally referenced to the residual solvent peak. 
Coupling constants (7) are given in Hertz (Hz) to the nearest 0.5 Hz. Liquid Chromatography 
Mass Spectroscopy (LCMS) analysis was conducted on either System A, a Waters Acquity 
UPLC BEH C18 column (50 mm x 2.1 mm i.d. 1.7 µm packing diameter) at 40 
oC eluting with 
0.1 % v/v solution of formic acid in water (solvent A) and 0.1 % v/v solution of formic acid in 
acetonitrile (solvent B), using the following elution gradient 0.0$1.5 min 3$100% B, 1.5$1.9 min 
100% B, 1.9$2.0 min 3% B, at a flow rate of 1 mL/min; or System B, a Waters Acquity UPLC 
BEH C18 column (50 mm x 2.1 mm i.d. 1.7 µm packing diameter) at 40 
oC eluting with 10 mM 
ammonium bicarbonate in water adjusted to pH 10 with ammonia solution (solvent A) and 
acetonitrile (solvent B), using the following elution gradient 0.0$1.5 min 1$97% B, 1.5$1.9 min 
97% B, 1.9$2.0 min 100% B, at a flow rate of 1 mL/min. The UV detection was based on an 
average signal from wavelength of 210 nm to 350 nm. The mass spectra were recorded on a 
Waters ZQ mass spectrometer using alternate$scan positive and negative mode electrospray 
ionisation. Preparative HPLC using a Mass Directed Auto Purification (MDAP) were conducted 
on a Waters 0
	%4 system comprising of a Waters 515 pump with extended pump heads, 
Waters 2767 auto sampler, Waters 996 photodiode array detector and Gilson 202 fraction 
collector on an XBridge or Sunfire C18 column (30 mm x 150 mm i.d. 5µm packing diameter) at 
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ambient temperature. The mobile phase was 0.1 % v/v solution formic acid in water or 10 mM 
ammonium bicarbonate in water adjusted to pH 10 with ammonia solution (solvent A) and 0.1 % 
v/v solution formic acid in acetonitrile or acetonitrile (solvent B). The UV detection is a summed 
signal from wavelength of 210 nm to 350 nm. The mass spectra were recorded on Waters ZQ 
mass spectrometer using alternate$scan positive and negative electrospray ionisation. The 
software used was %4 3.5 with 82%4and 0
	%4 options. High resolution 
mass spectra (HRMS) were obtained on a Micromass Q$Tof Ultima hybrid quadrupole time$of$
flight mass spectrometer, equipped with a Z$spray interface (ESI), over a mass range of 100 – 
1100 Da, with a scan time of 0.9 s and an interscan delay of 0.1 s. Reserpine was used as the 
external mass calibrant ([M+H]+ = 609.2812 Da). The Q$Tof Ultima mass spectrometer was 
operated in W reflectron mode to give a resolution (FWHM) of 16000$20000. Ionisation was 
achieved with a spray voltage of 3.2 kV, a cone voltage of 50 V, with cone and desolvation gas 
flows of 10$20 and 600 L/hr, respectively. The source block and desolvation temperatures were 
maintained at 120 ºC and 250 ºC respectively. The elemental composition was calculated using 
%4v4.1 for the [M+H]+ and the mass error quoted as ppm. Flash column chromatography 
was conducted on a Combiflash® Rf, automated flash chromatography system (Teledyne Isco) 
using disposable normal or reverse phase Redisep cartridges (4 g to 330 g). The CombiFlash® 
Rf used RFID (Radio Frequency Identification Detector) technology to automate setting the 
parameters for purification runs and fraction collection. The system was equipped with a UV 
variable dual$wavelength and a Foxy® fraction collector enabling automated peak cutting, 
collection and tracking. The purity of all compounds screened in the biological assays was 
examined by LCMS analysis and was found to be ≥ 95 % unless otherwise specified. The human 
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biological samples were sourced ethically and their research use was in accord with the terms of 
the informed consents.  
Compounds &, ., and $0	were purchased from Enamine. Compound $& was purchased from 
Vitas.  Compound $9	was purchased from ChemDiv. Compounds $)	0)	/)	7)	8)	9)	$2)	$.)	$/)	..)	
and .0	were obtained from the GSK compound collection, but are also available from 
commercial suppliers. Compound ./ was obtained from the GSK compound collection and may 
be synthesised according to the procedure described by Azizian and co$workers.21 
 9:
49&9
49'99-'9	424;<&9a=24			919+	
	>?was 
obtained from the GSK compound collection. 1H NMR (500 MHz, DMSO$d6) δ ppm 5.78 (s, 1 
H), 4.36 (q, 7= 7.0 Hz, 2 H), 2.47 $ 2.52 (m, 1 H), 2.27 (s, 3 H). 1.36 (t, 7= 7.0 Hz, 3 H); LCMS 
(ESI, formic) @; 219.01 [M+H]+, Rt = 0.63 min.	
&9
49-991-9	4
	< 19d=24			9A9+4		>?$Lithium 
hydroxide, monohydrate (2.3 g, 55 mmol) was added to a solution of ethyl 5$methyl$4$oxo$3,4$
dihydrothieno[2,3$]pyrimidine$6$carboxylate	(4.0 g, 17 mmol) in a mixture of THF (50 mL), 
MeOH (25 mL) and water (8 mL). The reaction mixture was stirred at room temperature for 16 
h. Lithium hydroxide, monohydrate (1.0 g, 24 mmol) was added and the reaction mixture was 
stirred for another 6 h. The reaction mixture was then heated at 40 °C for 24 h. Solvent was 
evaporated under reduced pressure. The resulting crude product was dissolved in water and the 
mixture was acidified to pH 1 with 2 M aqueous HCl solution. The resulting precipitate was 
collected by filtration and dried in a vacuum oven overnight to give the title product as a pale 
pink solid (3.5 g, 99 %).  1H NMR (400 MHz, DMSO$d6) δ 13.31 (br. s, 1H), 12.56 (br. s, 1H), 
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8.17 (s, 1H), 2.80 (s, 3H); LCMS (ESI, formic) @; 211.02 [M+H]+, Rt = 0.45 min; HRMS (ESI) 
calcd for C8H6N2O3S+H
+ 211.0177, found 211.0172 (2.95 min). 
@	(				(	
The appropriate amine (1.2 eq), HATU (1.2 eq) and DIPEA (2 eq) were added to a solution of 
3,5$dimethyl$4$oxo$3,4$dihydrothieno[2,3$]pyrimidine$6$carboxylic acid (0) (1 eq) in DMF (4 $ 
10 mL). The mixture was stirred at room temperature until reaction was complete by LCMS. 
Water (50 mL) and EtOAc (50 mL) were added. The aqueous phase was extracted with EtOAc 
(2 x 50 mL). The organic layers were combined, passed through a hydrophobic frit and 
concentrated to dryness under reduced pressure. The resulting crude product was purified by 
reverse phase chromatography to give the desired final product.  
@	(				(	
HATU (1.2 eq) and DIPEA (2 eq) were added to a solution of 5$methyl$4$oxo$3,4$
dihydrothieno[2,3$]pyrimidine$6$carboxylic acid ($7) (1 eq) in DMF (1.5 – 2.5 mL). The 
mixture was stirred at room temperature between 1 to 10 min. The appropriate amine (1.2 eq) 
was then added and the reaction mixture was stirred at room temperature until reaction was 
complete by LCMS. Solvent was then evaporated under reduced pressure. The resulting crude 
product was purified by reverse phase chromatography to give the desired final product.  
1&9	
49-99N92491-9	4
	< 19d=24			9A9+	>?was 
prepared according to general procedure A using aniline (50 µL, 0.54 mmol). The resulting crude 
product was purified by reverse phase chromatography using the formic acid MDAP (gradient B 
over 15 min) to give the title product as white solid (90 mg, 64 %). 1H NMR (400 MHz, DMSO$
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d6) δ 10.25 (s, 1H), 8.50 (s, 1H), 7.68 (br. d, 7 = 7.5 Hz, 2H), 7.36 (br. t, 7 = 8.0 Hz, 2H), 7.07 $ 
7.16 (br. t, 7 = 7.5 Hz, 1H), 3.49 (s, 3H), 2.74 (s, 3H); LCMS (ESI, high pH) @; 300.04 
[M+H]+, Rt = 0.83 min. 
&9
49-99N92491-9	4
	< 19d=24			9A9+	>	?was 
prepared according to general procedure B using aniline (50 µL, 0.54 mmol). The crude product 
was purified by reverse phase chromatography (C18 column, 10$40 % CH3CN (B) / 10 mM 
aqueous ammonium bicarbonate solution (A)) to give the title product as a pale yellow solid (87 
mg, 64 %). 1H NMR (400 MHz, DMSO$d6) δ 12.57 (br. s, 1H), 10.20 (s, 1H), 8.18 (s, 1H), 7.68 
(d, 7 = 7.5 Hz, 2H), 7.36 (t, 7 = 8.0 Hz, 2H), 7.03 $ 7.18 (m, 1H), 2.73 (s, 3H); 13C NMR (101 
MHz, DMSO$d6) δ 164.2 (C), 160.6 (C=O), 158.3 (C=O), 147.4 (Ar$CH), 138.5 (C), 136.4 (C), 
128.7 (2C, Ar$CH), 127.9 (C), 124.0 (Ar$CH), 123.4 (C), 120.3 (2C, Ar$CH), 15.1 (CH3); LCMS 
(ESI, high pH) @; 286.01 [M+H]+, Rt = 0.72 min; HRMS (ESI) calcd for C14H11N3O2S+H
+ 
286.0650, found 286.0646 (4.08 min); IR (ATR) cm$1 3294, 3062, 3020, 2929, 2866, 1656, 
1634, 1595, 1580, 1529. 
N942
491&9	
49-991-9	4
	< 19d=24			9A9+	>
?
was prepared according to general procedure A using cyclopentanamine (0.026 mL, 0.268 mmol. 
Purification twice by reverse phase chromatography using the formic acid MDAP (gradient B 
over 15 min) gave the title product as a white solid (20 mg, 28 %). 1H NMR (400 MHz, CDCl3) 
δ 8.03 (s, 1H), 5.82 (d, 7 = 6.5 Hz, 1H), 4.39 (apparent sxt, 7 = 7.0 Hz, 1H), 3.58 (s, 3H), 2.86 (s, 
3H), 2.05 – 2.17 (m, 2H), 1.62 $ 1.81 (m, 4H), 1.45 $ 1.57 (m, 2H); LCMS (ESI, formic) @; 
292.09 [M+H]+, Rt = 0.78 min.  
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1&9	
49A9>2	2		99+4?
	< 19d=24			9->1H?9>?was prepared 
according to general procedure A using piperidine (0.04 mL, 0.43 mmol). Purification by reverse 
phase chromatography using the formic acid MDAP (gradient B over 15 min) gave the title 
product as a white solid (70 mg, 64 %). 1H NMR (400 MHz, DMSO$d6) δ 8.43 (s, 1H), 3.47 (br. 
s, 7H), 2.43 (s, 3H), 1.56 $ 1.67 (m, 2H), 1.55$1.44 (m, 4H); LCMS (ESI, formic) @; 292.17 
[M+H]+, Rt = 0.74 min. 
&9
49-99N9>o9
4?91-9	4
	< 19d=24			9A9+	>?was 
prepared according to general procedure B using $toluidine (0.4 mL, 0.3 mmol). Purification by 
reverse phase chromatography using the formic acid MDAP (gradient B over 15 min) gave the 
title product as yellow solid (32 mg, 37 %). 1H NMR (400 MHz, DMSO$d6) δ 12.55 (br. s, 1H), 
9.69 (s, 1H), 8.17 (s, 1H), 7.39 (br. d, 7 = 7.5 Hz, 1H), 7.28 (br. d, 7 = 7.0 Hz, 1H), 7.15 $ 7.25 
(m, 2H), 2.79 (s, 3H), 2.26 (s, 3H); LCMS (ESI, formic) @; 300.04 [M+H]+, Rt = 0.78 min, 
purity = 94 %. 
&9
49-99N9>m9
4?91-9	4
	< 19d=24			9A9+	>?was 
prepared according to general procedure B using $toluidine (60 µL, 0.57 mmol). Purification 
by reverse phase chromatography using the formic acid MDAP (gradient B over 15 min) gave 
the title product as a white solid (39 mg, 46 %). 1H NMR (400 MHz, DMSO$d6) δ 12.55 (br. s, 
1H), 10.12 (s, 1H), 8.17 (s, 1H), 7.51 (s, 1H), 7.47 (d, 7 = 8.5 Hz, 1H), 7.23 (t, 7 = 8.0 Hz, 1H), 
6.94 (d, 7 = 7.5 Hz, 1H), 2.73 (s, 3H), 2.31 (s, 3H); 13C NMR (101 MHz, DMSO$d6) δ 164.2 (C), 
160.5 (C=O), 158.3 (C=O), 147.3 (CH), 138.4 (C), 137.9 (C), 136.3(C), 128.5 (C), 128.0 (CH), 
124.7 (CH), 123.4 (C), 120.8 (CH), 117.5 (CH), 21.1 (CH3), 15.0 (CH3); LCMS (ESI, formic) 
@; 300.11 [M+H]+, Rt = 0.85 min; HRMS (ESI) calcd for C15H13N3O2S+H
+ 300.0801, found 
300.0798 (4.21 min).  
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&9
49-99N9>p9
4?91-9	4
	< 19d=24			9A9+	 (&.) was 
prepared according to general procedure B  using 2$toluidine (80 mg, 0.75 mmol). Purification 
by reverse phase chromatography using the formic acid MDAP (gradient B over 15 min) gave 
the title product as a white solid (39 mg, 45 %). 1H NMR (400 MHz, DMSO$d6) δ 12.54 (br. s, 
1H), 10.10 (s, 1H), 8.17 (s, 1H), 7.56 (d, 7 = 8.5 Hz, 2H), 7.16 (d, 7 = 8.5 Hz, 2H), 2.72 (s, 3H), 
2.28 (s, 3H); 13C NMR (101 MHz, DMSO$d6) δ 164.1 (C), 160.4 (C=O), 158.3 (C=O), 147.3 
(Ar$CH), 136.2 (C), 136.0 (C), 133.1 (C), 129.0 (2C, Ar$CH), 128.0 (C), 123.4 (C), 120.3 (2C, 
Ar$CH), 20.5 (CH3), 15.0 (CH3); LCMS (ESI, formic) @; 300.11 [M+H]
+, Rt = 0.85 min; 
HRMS (ESI) calcd for C15H13N3O2S+H
+ 300.0801, found 300.0803 (4.19 min).  
&9
49-99N9>24		9194?91-9	4
	< 19d=24			9A9+	>? was 
prepared according to general procedure B using pyridin$3$amine (57 mg, 0.61 mmol). 
Purification by reverse phase chromatography (5$20% acetonitrile (B) / 10 mM aqueous 
ammonium bicarbonate solution (A)). The product was dissolved in MeOH and transferred in a 
vial for test to give the title product as MeOH solvate, yellow solid (70 mg, 46 %). 1H NMR (400 
MHz, DMSO$d6) δ 12.59 (br. s, 1H), 10.39 (s, 1H), 8.84 (d, 7 = 2.5 Hz, 1H), 8.33 (dd, 7 = 5.0, 
1.5 Hz, 1H), 8.19 (s, 1H), 8.07 $ 8.14 (m, 1H), 7.40 (dd, 7 = 8.5, 5.0 Hz, 1H), 4.06 (d, 7 = 5.0 Hz, 
1H, CH3OH), 3.17 (d, 7 = 5.0 Hz, 3H, CH3OH), 2.76 (s, 3H); LCMS (ESI, high pH) @;286.99 
[M+H]+, Rt = 0.52 min.  
!9>	;9194?9&9
49-991-9	4
	< 19=24			9A9+	>? 
A solution of 5$methyl$4$oxo$3,4$dihydrothieno[2,3$]pyrimidine$6$carboxylic acid $7 (100 
mg, 0.48 mmol) in thionyl chloride (2 mL, 27 mmol) was heated at 80 ºC for 3 days before the 
reaction mixture was concentrated to dryness under reduced pressure. A solution of isoxazol$3$
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amine (160 mg, 1.9 mmol) and DIPEA (0.2 mL, 1.2 mmol) in DMF (1.5 mL) dried over 
molecular sieves (4 Å) was added to the crude and the reaction mixture was stirred at room 
temperature with molecular sieves for 24 h. The crude reaction mixture was purified by reverse 
phase chromatography using formic acid MDAP (gradient A over 15 min) to give the title 
product as white solid (18 mg, 14 %). 1H NMR (400 MHz, DMSO$d6) δ 11.98 (br. s, 2H), 8.85 
(d, 7 = 1.5 Hz, 1H), 8.19 (s, 1H), 6.97 (d, 7 = 2.0 Hz, 1H), 2.75 (s, 3H); LCMS (ESI, formic) @; 
277.06 [M+H]+, Rt = 0.57 min. 
&9
49-99N9>
	29 94?91-9	4
	< 19d=24			9A9+	>? 
was prepared according to general procedure B using thiophen$2$amine (64 mg, 0.65 mmol) at 
40 °C. Purification by reverse phase chromatography using the formic acid MDAP (gradient B 
over 15 min) to give the title product as a brown solid (21 mg, 15 %). 1H NMR (400 MHz, 
DMSO$d6) δ 12.59 (br. s, 1H), 11.42 (s, 1H), 8.19 (d, 7 = 4.0 Hz, 1H), 7.05 (t, 7 = 4.0 Hz, 1H), 
6.90 $ 6.93 (m, 2H), 2.76 (s, 3H); 13C NMR (101 MHz, DMSO$d6) δ 164.4 (C), 158.5 (C=O), 
158.2 (C=O), 147.6 (Ar$CH), 139.2 (C), 138.0 (C), 125.4 (C), 124.1 (C), 123.5 (Ar$CH), 117.9 
(Ar$CH), 112.8 (Ar$CH), 15.1 (CH3); LCMS (ESI, formic) @; 292.03 [M+H]
+, Rt = 0.74 min; 
HRMS (ESI) calcd for C12H9N3O2S2+H
+ 292.0214, found 292.0214 (4.01 min). 
&9
49-99N$>1-9
		;9 94?91-9	4
	< 19d=24			9A9+	 
(&8) was prepared according to general procedure B using 2$amino$1,3,4$thiadiazole (62 mg, 
0.613 mmol) at 40 ºC. DMSO (2 mL) was added to the reaction mixture and the whole 
solubilised with heating. After cooling a solid precipitated out which was collected by filtration 
and dried in a vacuum oven overnight to give the title product as yellow solid (70 mg, 50 %). 1H 
NMR (400 MHz, DMSO$d6) δ 14.10 (br. s, 1H), 12.54 (br. s, 1H), 9.04 (br. s, 1H), 8.18 (d, 7 = 
3.5 Hz, 1H), 2.89 (s, 3H); 13C NMR (126 MHz, DMSO$d6) δ 167.6 (C), 166.7 (C=O), 158.5 
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(C=O), 146.2 (Ar$CH), 144.9 (Ar$CH), 135.6 (C), 134.2 (C), 124.2 (C), 109.5 (C), 14.8 (CH3); 
LCMS (ESI, formic) @; 294.03 [M+H]+, Rt = 0.38 min; HRMS (ESI) calcd for 
C10H7N5O2S2+H
+ 294.0119, found 294.0115 (3.22 min); IR (ATR) cm$1 3142, 3095, 3007, 2930, 
1676, 1651, 1552. 
:
4 9> 9>&9
49-991-9	4
	< 19d=24			9A9
+	?24?

>	?was prepared according to general procedure B using ethyl 2$
(2$aminophenyl)acetate 09 (66 mg, 0.4 mmol). The crude product was purified by reverse phase 
chromatography using formic acid MDAP (gradient B over 15 min) to give the title product as a 
yellow solid (46 mg, 40 %). 1H NMR (400 MHz, DMSO$d6) δ 12.56 (br. s, 1H), 9.75 (s, 1H), 
8.17 (d, 7 = 4.0 Hz, 1H), 7.42 (br. d, 7 = 8.0 Hz, 1H), 7.29 $ 7.36 (m, 2H), 7.19 $ 7.28 (m, 1H), 
4.04 (q, 7 = 7.0 Hz, 2H), 3.73 (s, 2H), 2.76 (s, 3H), 1.13 (t, 7 = 7.0 Hz, 3H); LCMS (ESI, formic) 
@; 372.07 [M+H]+, Rt = 0.83 min. 
 9> 9>&9
49-991-9	4
	< 19d=24			9A9+	?24?
		
>
? A solution of ethyl 2$(2$(5$methyl$4$oxo$3,4$dihydrothieno[2,3$d]pyrimidine$6$
carboxamido)phenyl)acetate &9	(30 mg, 0.1 mmol) and lithium hydroxide (5.8 mg, 0.2 mmol) in 
a mixture of THF (0.4 mL), MeOH (0.2 mL) and water (0.1 mL) was stirred at room temperature 
for 2 h. Solvents were removed under a stream of nitrogen. The resulting crude product was 
dissolved in water (0.5 mL) and 2 M aqueous HCl solution was added. The resulting precipitate 
was collected by filtration and dried in a vacuum oven overnight to give the title product as a 
brown solid (16 mg, 58 %). 1H NMR (400 MHz, DMSO$d6) δ 12.55 (br. s, 1H), 12.41 (br. s, 
1H), 9.74 (s, 1H), 8.17 (d, 7 = 3.5 Hz, 1H), 7.46 (br. d, 7 = 7.5 Hz, 1H), 7.28 $ 7.36 (m, 2H), 7.18 
$ 7.25 (m, 1H), 3.66 (s, 2H), 2.77 (s, 3H); LCMS (ESI, formic) @; 344.09 [M+H]+, Rt = 0.64 
min. 
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N9> 9>44
4?24?9&9
49-991-9	4
	< 19d=24			9A9
+	>?TBAF (1 M in THF, 0.39 mL, 0.39 mmol) was added to a solution of N$(2$
(((

9butyldimethylsilyl)oxy)methyl)phenyl)$5$methyl$4$oxo$3,4$dihydrothieno[2,3$
d]pyrimidine$6$carboxamide /2 (83 mg, 0.2 mmol) in THF (1 mL). The reaction mixture was 
stirred at room temperature for 3 h. Saturated aqueous NaHCO3 solution (10 mL) and EtOAc (10 
mL) were added. The organic layer was separated and the aqueous was extracted with EtOAc (2 
x 10 mL). The combined organic layers were passed through a hydrophobic frit and concentrated 
under reduced pressure. The crude product was purified by reverse phase chromatography using 
the formic acid MDAP (gradient C over 15 min) to give the title product as a white solid (36 mg, 
59 %). 1H NMR (400 MHz, DMSO$d6) δ 12.57 (br. s, 1H), 9.87 (br. s, 1H), 8.18 (s, 1H), 7.79 
(br. d, 7 = 8.0 Hz, 1H), 7.40 (br. d, 7 = 7.5 Hz, 1H), 7.30 (br. t, 7 = 8.0 Hz, 1H), 7.19 (br. t, 7 = 
7.5 Hz, 1H), 5.63 (br. s, 1H), 4.61 (s, 2H), 2.83 (s, 3H); LCMS (ESI, formic) @; 316.00 
[M+H]+, Rt = 0.67 min; HRMS (ESI) calcd for C15H13N3O3S+H
+ 316.0741, found 316.0756 
(3.68min). 
&9
49-99N9> 9424?91-9	4
	< 19d=24			9A9+	
>?$	A solution of 5$methyl$4$oxo$3,4$dihydrothieno[2,3$]pyrimidine$6$carboxylic acid $7 (60 
mg, 0.29 mmol) in thionyl chloride (2 mL, 27 mmol) was refluxed for 16 h before the reaction 
mixture was concentrated under reduced pressure. A solution of 2$aminobenzenesulfonamide 
(59.0 mg, 0.34 mmol) and DIPEA (0.1 mL, 0.6 mmol) in DMF (1.5 mL) was dried over 
molecular sieves (4 Å) and then added to the acid chloride intermediate under nitrogen. The 
reaction mixture was stirred at room temperature under nitrogen for 5 h. The crude product was 
purified by reverse phase chromatography using the formic acid MDAP (gradient A over 15 min) 
to give the title product as an orange solid (11 mg, 11 %). 1H NMR (400 MHz, DMSO$d6) δ 
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12.56 (br. s, 1H), 8.17 (d, 7 = 3.5 Hz, 1H), 7.67 (dd, 7 = 8.0, 1.5 Hz, 1H), 7.29 $ 7.36 (m, 1H), 
6.84 (d, 7 = 8.5 Hz, 1H), 6.68 $ 6.74 (m, 1H), 2.69 (s, 3H), amide NH and NH2 protons not 
visible; LCMS (ESI, formic) @; 364.97 [M+H]+, Rt = 0.62 min.  
&9
49N9> 9>
44?24?9-991-9	4
	< 19d=24			9A9
+	>?$5$methyl$4$oxo$3,4$dihydrothieno[2,3$]pyrimidine$6$carboxylic acid $7 
(100 mg, 0.48 mmol) in thionyl chloride (2 mL, 27 mmol) was heated at 50 °C for 2 days before 
the reaction mixture was concentrated under reduced pressure. A solution of DMF (1.5 mL) and 
DIPEA (0.2 mL, 1.1 mmol) dried over molecular sieves (4 Å) was added to the crude 
intermediate followed by 2$(methylsulfonyl)aniline (250 mg, 1.5 mmol). The reaction mixture 
was stirred at room temperature with molecular sieves under nitrogen for 16 h before being 
heated to 50 °C for a further 16 h. The crude mixture was purified by reverse phase 
chromatography using the formic acid MDAP (gradient B over 15 min) to give the title product 
as a yellow solid (16 mg, 9 %). 1H NMR (400 MHz, DMSO$d6) δ 8.19 $ 8.24 (m, 2H), 7.96 (dd, 
7 = 8.0, 1.5 Hz, 1H), 7.75 $ 7.81 (m, 1H), 7.47 (td, 7 = 8.5, 1.0 Hz, 1H), 3.33 (s, 3H), 2.85 (s, 
3H), amide NH protons not visible; LCMS (ESI, formic) @; 364.11 [M+H]+, Rt = 0.76 min. 
N9>-9+424?91-9	+;	>?$HATU (191 mg, 0.5 mmol), 4$
aminobenzamide (68 mg, 0.5 mmol) and DIPEA (0.15 mL, 0.84 mmol) were added to a solution 
of 3,4$dichlorobenzoic acid (80 mg, 0.42 mmol) in DMF (1.5 mL) and the reaction mixture was 
stirred at room temperature for 3 h. Saturated aqueous sodium bicarbonate solution (25 mL) was 
added and the aqueous phase was extracted with DCM (2 x 25 mL). Solid was present in both 
phases. The solid was collected by filtration under vacuum and dried in a vacuum oven to give 
the title product as a white solid (87 mg, 65 %). 1H NMR (400 MHz, DMSO$d6) δ 10.55 (br. s, 
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1H), 8.23 (d, 7 = 2.0 Hz, 1H), 7.95 (dd, 7 = 8.5, 2.0 Hz, 1H), 7.77 $ 7.91 (m, 6H), 7.24 (br. s, 
1H); LCMS (ESI, formic) @; 309.03 [M+H]+, Rt = 0.92 min. 
@	5			B:	(	
A mixture of the appropriate aryl halide (1 eq.), (1$pyrazol$3$yl)boronic acid.3H2O (2 eq.), 
Pd(PPh3)4 (15 mol%), NMP and saturated aqueous sodium carbonate solution (1 eq.) was heated 
at 130 oC for 20 min in a microwave reactor. The reaction mixture was filtered and solvent was 
evaporated. The crude product was purified by reverse phase chromatography to give the desired 
final product
N9>-9>H924;9194?24?+;	>?was prepared according to general procedure C 
using !$(4$bromophenyl)benzamide 0.	(55 mg, 0.2 mmol). The crude product was purified by 
reverse phase chromatography using the formic acid MDAP (gradient B over 15 min) to give the 
title product as a white solid (35 mg, 67 %). 1H NMR (400 MHz, DMSO$d6) δ 13.20$12.80 (2 br. 
s, 1H, two pyrazole isomers visible), 10.27 (br. s, 1H), 7.93 $ 8.01 (m, 2H), 7.70 $ 7.88 (m, 5H), 
7.48 $ 7.64 (m, 3H), 6.68 (br. s, 1H); LCMS (ESI, formic) @; 264.11 [M+H]+, Rt = 0.82 min; 
HRMS (ESI) calcd for C16H13N3O+H
+ 264.1131, found 264.1125 (3.99 min).  
 9> 9>>-9>H924;9194?24?+4?24?
		>	?was prepared according 
to general procedure C using methyl 2$(2$((4$bromophenyl)carbamoyl)phenyl)acetate 00 (60 mg, 
0.172 mmol. The crude product was purified by reverse phase chromatography using the formic 
acid MDAP (gradient B over 15 min) to give the title product as a white solid (33 mg, 60 %). 1H 
NMR (600 MHz, DMSO$d6) δ 12.59 (br. s, 1H), 10.47 (br. s, 1H), 7.73 $ 7.79 (m, 5H), 7.68 (br. 
s, 1H), 7.60 (d, 7 = 7.5 Hz, 1H), 7.44 $ 7.48 (m, 1H), 7.34 $ 7.42 (m, 2H), 6.65 (d, 7 = 2.0 Hz, 
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1H), 3.84 (s, 2H); LCMS (ESI, formic) @; 322.07 [M+H]+, Rt = 0.72 min; HRMS (ESI) calcd 
for C18H15N3O3+H
+ 322.1186, found 322.1187 (3.64min).  
N9>-9+424?+;	>
?$HATU (300 mg, 0.8 mmol), 4$aminobenzamide (107 
mg, 0.8 mmol) and DIPEA (0.23 mL, 1.3 mmol) were added to a solution of benzoic acid (80 
mg, 0.66 mmol) in DMF (1.5 mL) and the reaction mixture was stirred at room temperature 
overnight. Saturated aqueous sodium bicarbonate solution (25 mL) was added and the aqueous 
phase was extracted with DCM (2 x 25 mL). Some solid remained in the aqueous phase and was 
collected by filtration. LCMS of the solid and the organic phase showed desired product present 
in both. The organic phase was passed through a hydrophobic frit and concentrated under 
reduced pressure. The resulting crude product was combined with the solid isolated by filtration 
prior purification. The resulting crude was purified by reverse phase chromatography using the 
formic acid MDAP (gradient B over 15 min) to give the title product as a white solid (67 mg, 41 
%). 1H NMR (400 MHz, DMSO$d6) δ 10.41 (s, 1H), 7.92 $ 8.02 (m, 2H), 7.78 $ 7.92 (m, 5H), 
7.57 $ 7.66 (m, 1H), 7.49 $ 7.58 (m, 2H), 7.22 (br. s, 1H); 13C NMR (101 MHz, DMSO$d6) δ 
167.3 (C=O), 165.8 (C=O), 141.8 (C), 134.7 (C), 131.7 (2C, Ar$CH), 129.1 (2C, Ar$CH), 128.4 
(2C, Ar$CH), 128.2 (2C, Ar$CH), 127.7 (C), 119.3 (Ar$CH); LCMS (ESI, formic) @; 241.11 
[M+H]+, Rt = 0.66 min; HRMS (ESI) calcd for C14H12N2O2+H
+ 241.0972, found 241.0967 (3.29 
min); IR (ATR) cm$1 3383, 3308, 3163, 1650, 1606, 1516.  
-9>991-9	4	B		9 >H?94?+;	>?$A mixture of 4$(1$oxo$3,4$
dihydroisoquinolin$2(1)$yl)benzonitrile 07 (40 mg, 0.16 mmol), 2 M aqueous NaOH solution 
(1.2 mL, 2.4 mmol) and 30 % aqueous H2O2 solution (54 µL, 0.53 mmol) in EtOH (1 mL) was 
heated at 50 ºC for 20 h. The reaction mixture was poured in saturated aqueous sodium sulfite 
solution and acidified to pH 1 with aqueous H2SO4 solution. The mixture was concentrated under 
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reduced pressure. Water and DCM were added. The aqueous phase was extracted with DCM. 
The combined organic phases were passed through a hydrophobic frit and concentrated under 
reduced pressure. The resulting crude product was purified by reverse phase chromatography 
using the formic acid MDAP (gradient B over 15 min) to give the title product as a white solid (8 
mg, 19 %); 1H NMR (400 MHz, DMSO$d6) δ 7.86 $ 8.00 (m, 4H), 7.45 $ 7.58 (m, 3H), 7.35 $ 
7.44 (m, 2H), 7.27 $ 7.34 (m, 1H), 4.00 (t, 7 = 6.5 Hz, 2H), 3.14 (t, 7 = 6.5 Hz, 2H); LCMS (ESI, 
formic) @; 267.07 [M+H]+, Rt = 0.71 min; HRMS (ESI) calcd for C16H15N2O2+H
+ 267.1128, 
found 267.1125 (3.56 min).  
N9> 9>H924;9194?24			9&94?+;	>?	was prepared according to general 
procedure C using!$(2$chloropyrimidin$5$yl)benzamide 0/ (60 mg, 0.26 mmol). The resulting 
crude product was purified by reverse phase chromatography using the high pH MDAP (gradient 
B over 15 min) to give the title product as a white solid (28 mg, 41 %). 1H NMR (400 MHz, 
DMSO$d6) δ 13.02 $ 13.79 (br. d, 1H, two pyrazole isomers visible), 10.68 (br. s, 1H), 9.23 (s, 
2H), 8.00 $ 8.05 (m, 2H), 7.62 $ 7.68 (m, 2H), 7.55 $ 7.61 (m, 2H), 6.90 (d, 7 = 1.5 Hz, 1H); 13C 
NMR (101 MHz, DMSO$d6) δ 177.6 (Ar$CH), 165.9 (C=O), 148.5 (2C, Ar$CH), 133.7 (C), 
132.6 (C), 132.2 (Ar$CH), 128.5 (2C, Ar$CH), 127.7 (2C, Ar$CH), 119.1 (C), 105.4 (Ar$CH), 
one carbon too weak to assign should be around 150 ppm; LCMS (ESI, high pH) @; 266.04 
[M+H]+, Rt = 0.74 min; HRMS (ESI) calcd for C14H11N5O+H
+ 266.1029, found 266.1036 
(3.47min).  
 9>-9>924;9194?24?91-9	4	B		9> H?9>? was prepared according 
to general procedure C using 2$(4$bromophenyl)$3,4$dihydroisoquinolin$1(2)$one 08 (100 mg, 
0.331 mmol). The resulting crude product was purified by reverse phase chromatography using 
the formic acid MDAP (15$55%(B) over 15 mins) to give the title product as a white solid (45 
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mg, 47 %). 1H NMR (400 MHz, DMSO$d6) δ 13.31 + 12.89 (2 br. s, 1H), 7.95 (dd, 7= 7.5, 1.0 
Hz, 1H), 7.75 $ 7.88 (m, 3H), 7.54 (td, 7= 7.5, 1.5 Hz, 1H), 7.46 (br. s, 1H), 7.36$7.43 (m, 3H), 
6.73 (br. s, 1H), 3.99 (t, 7= 6.5 Hz, 2H), 3.15 (t, 7= 6.5 Hz, 2H); LCMS (ESI, high pH) @; 
290.23 [M+H]+, Rt = 0.89 min. 
N9>-9+24?+;	>?$HATU (335 mg, 0.88 mmol) and DIPEA (0.26 mL, 1.5 
mmol) were added to a solution of benzoic acid (90 mg, 0.74 mmol) in DMF (3 mL). The 
mixture was stirred at room temperature for 5 min. 4$bromoaniline (152 mg, 0.88 mmol) was 
then added and the reaction mixture was stirred at room temperature for 15 h. The crude reaction 
mixture was purified by reverse phase chromatography (30$85 % CH3CN + 0.01 % formic acid 
(B) / H2O + 0.01 % formic acid (A), 43 g C18 column) to give the title product as a white solid 
(120 mg, 49 %). 1H NMR (400 MHz, DMSO$d6) δ 10.34 (s, 1H), 7.94 (br. d, 7 = 7.0 Hz, 2H), 
7.77 (br. d, 7 = 9.0 Hz, 2H), 7.59$7.62 (m, 1H), 7.50 $ 7.56 (m, 4H); LCMS (ESI, formic) @; 
275.97 + 277.93 [M+H]+, Rt = 1.09 min.  

4 9> 9>>-9+24?+4?24?

>?$HATU (335 mg, 0.88 mmol) 
and DIPEA (0.26 mL, 1.49 mmol) were added to a solution of 2$(2$methoxy$2$oxoethyl)benzoic 
acid (135 mg, 0.69 mmol) in DMF (3 mL). The mixture was stirred at room temperature for 5 
min. 4$bromoaniline (152 mg, 0.88 mmol) was then added and the reaction mixture was stirred at 
room temperature for 15 h. The crude reaction mixture was purified by reverse phase 
chromatography (30$85 % CH3CN + 0.01 % formic acid (B) / H2O + 0.01 % formic acid (A), 43 
g C18 column) to give the title product as a beige solid (210 mg, 68 %). 1H NMR (400 MHz, 
DMSO$d6) δ 10.44 (s, 1H), 7.69 (br. d., 7 = 9.0 Hz, 2H), 7.60 (br. d, 7 = 7.5 Hz, 1H), 7.34 $ 7.54 
(m, 5H), 3.90 (s, 2H), 3.53 (s, 3H); LCMS (ESI, formic) @; 347.97, 349.93 [M+H]+, Rt = 1.08 
min.  
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N9> 924			9&94?+;	>?$HATU (747 mg, 1.96 mmol) and DIPEA (0.57 
mL, 3.27 mmol) were added to a solution of benzoic acid (200 mg, 1.64 mmol) in DMF. The 
mixture was stirred at room temperature for 5 min. 2$Chloropyrimidin$5$amine (255 mg, 1.97 
mmol) was then added and the reaction mixture was stirred at room temperature for 3 h. The 
reaction mixture was then heated at 40 °C for 15 h. Additional 2$chloropyrimidin$5$amine (125 
mg, 0.97 mmol) was added and the reaction mixture was heated at 40 °C for 5 h. Solvent was 
evaporated under reduced pressure. The resulting crude product was purified by reverse phase 
chromatography (20$60 % MeOH (B) / water + 0.1 % formic acid (A), C18 GOLD column) to 
give the title product as a brown solid (175 mg, 46 %). 1H NMR (400 MHz, DMSO$d6) δ 10.77 
(br. s, 1H), 9.14 (s, 2H), 7.98 $ 8.02 (m, 2H), 7.62 $ 7.69 (m, 1H), 7.58 (apparent triplet, 7 = 7.0, 
8.0 Hz, 2H); LCMS (ESI, high pH) @; 234.09 [M+H]+, Rt = 0.84 min. 
-9>991-9	4	B		9 >H?94?+;	
	>?$A mixture of 3,4$
dihydroisoquinolin$1(2)$one (62 mg, 0.42 mmol), 4$iodobenzonitrile (195 mg, 0.85 mmol), 
potassium carbonate (59 mg, 0.43 mmol) and copper(I) iodide (16 mg, 0.084 mmol) in DMF (1 
mL) was heated at 160 °C overnight under nitrogen. The reaction mixture was cooled and poured 
into saturated aqueous NH4OH solution and EtOAc. The phases were separated and the aqueous 
phase was extracted with EtOAc. The combined organic phases were washed with brine, 
separated, passed through a hydrophobic frit and concentrated under reduced pressure. The 
resulting crude product was then purified by reverse phase chromatography using the formic acid 
MDAP (gradient C over 15 min) to give the title product as a white solid (69 mg, 66 %). 1H 
NMR (400 MHz, DMSO$d6) δ 7.93 $ 7.99 (m, 1H), 7.88 (d, 7 = 9.0 Hz, 2H), 7.66 (d, 7 = 9.0 Hz, 
2H), 7.56 (td, 7 = 7.5, 1.5 Hz, 1H), 7.36 $ 7.44 (m, 2H), 4.03 (t, 7 = 6.5 Hz, 2H), 3.15 (t, 7 = 6.5 
Hz, 2H); LCMS (ESI, formic) @; 249.12 [M+H]+, Rt = 0.94 min. 
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 9>-9+24?91-9	4	B		9> H?9>?$A mixture of 3,4$
dihydroisoquinolin$1(2)$one (200 mg, 1.36 mmol), 1$bromo$4$iodobenzene (769 mg, 2.72 
mmol), copper(I) iodide (52 mg, 0.27 mmol) and potassium carbonate (207 mg, 1.495 mmol) in 
DMF (3 mL) was heated at 160 ºC overnight. The reaction mixture was cooled and poured into 
saturated aqueous NH4OH solution and EtOAc. The two phases were separated and the aqueous 
phase was extracted with EtOAc. The combined organic phases were washed with brine, 
separated, passed through a hydrophobic frit and evaporated under reduced pressure. The 
resulting crude product was purified by reverse phase chromatography (Redisep C18 column 
GOLD, 50 g $ 40$85 % acetonitrile (B)/ water + 0.1 % formic acid (A) gradient) to give the title 
product as a white solid (242 mg, 59 %). 1H NMR (400 MHz, DMSO$d6) δ 7.94 (d, 7= 8.0 Hz, 
1H), 7.58$7.63 (m, 2H), 7.54 (td, 7= 7.5, 1.5 Hz, 1H), 7.34$7.42 (m, 4H), 3.95 (t, 7= 6.5 Hz, 
2H), 3.13 (t, 7= 6.5 Hz, 2H); LCMS (ESI, high pH) @; 301.77 + 303.75 [M+H]+, Rt = 1.09 min. 
:
4  9> 9	24?

 >	?$A solution of ethyl 2$(2$nitrophenyl)acetate (200 mg, 
0.96 mmol) in EtOH (40 mL) was pumped through an H$cube (10 % Pd/C catcart cartridge, 20 
°C, full H2). Solvent was evaporated under reduced pressure to give the title product as an orange 
gum (148 mg, 86 %). 1H NMR (400 MHz, DMSO$d6) δ 6.90 $ 6.99 (m, 2H), 6.65 (dd, 7 = 8.0, 
1.0 Hz, 1H), 6.51 (apparent dt, 7 = 7.5, 1.5 Hz, 1H), 4.84 (br. s, 2H), 4.07 (q, 7 = 7.0 Hz, 2H), 
3.49 (s, 2H), 1.18 (t, 7 = 7.0 Hz, 3H); LCMS (ESI, formic) @; 180.06 [M+H]+, Rt = 0.70 min. 
 9>>>

9+
4	
4	4?4?
4?		>
?$C
$butyldimethylsilyl chloride (673 mg, 
4.47 mmol) and imidazole (553 mg, 8.12 mmol) were added to a solution of (2$
aminophenyl)methanol (500 mg, 4.06 mmol) in CH2Cl2 (6 mL). The reaction mixture was stirred 
at room temperature for 14 h. CH2Cl2 (5 mL) and water (10 mL) were added and the organic 
layer was separated using a hydrophobic frit before being concentrated under reduced pressure to 
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give the title product as an orange liquid (889 mg, 92 %). 1H NMR (400 MHz, DMSO$d6) δ 7.07 
(br. d, 7 = 7.5 Hz, 1H), 6.96 (apparent dt, 7 = 7.5, 1.5 Hz, 1H), 6.62 (dd, 7 = 8.0, 1.0 Hz, 1H), 
6.54 (apparent dt, 7 = 7.5, 1.0 Hz, 1H), 4.83 (br. s., 2 H),  4.57 (s, 2H), 0.89 (s, 9H), 0.06 (s, 6H); 
LCMS (ESI, formic) @; 238.14 [M+H]+, Rt= 1.36 min. 
N9> 9>>>

9+
4	
4	4?4?
4?24?9&9
49-991-9	4
	< 19
d=24			9A9+	>?was prepared according to general procedure B using 2$(((

$
butyldimethylsilyl)oxy)methyl)aniline 01 (140 mg, 0.59 mmol). The crude product was purified 
by reverse phase chromatography (43 g C18 column, 40$80 % CH3CN + 0.1% formic acid (B) / 
H2O + 0.1% formic acid (A) over 25 min) to give the title product as a yellow solid (90 mg, 44 
%). 1H NMR (400 MHz, DMSO$d6) δ 12.57 (br. s, 1H), 9.63 (s, 1H), 8.18 (s, 1H), 7.60 (dd, 7 = 
8.0, 1.0 Hz, 1H), 7.46 (dd, 7 = 7.5, 1.0 Hz, 1H), 7.32 (apparent td, 7 = 8.0, 1.5 Hz, 1H), 7.26 
(apparent td, 7 = 7.5, 1.0 Hz, 1H), 4.77 (s, 2H), 2.80 (s, 3H), 0.87 (s, 9H), 0.06 (s, 6H). LCMS 
(ESI, formic) @; 430.14 [M+H]+, Rt = 1.32 min. 
,	4	
	4
	!		
GSK in$house kinetic solubility assay: 5 µL of 10 mM DMSO stock solution was diluted to 
100 µL with pH 7.4 phosphate buffered saline, equilibrated for 1 hour at room temperature and 
filtered through Millipore MultiscreenHTS$PCF filter plates (MSSL BPC). The filtrate was 
quantified by suitably calibrated flow injection Chemi$Luminescent Nitrogen Detection. The 
standard error of the CLND solubility determination is ±30 µM, the upper limit of the solubility 
was 500 µM when working from 10 mM DMSO stock solution.	
	5(	
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Calculated partition coefficient (clogP) was computed using the BioByte algorithm, version 
5.4 (BioByte Corp., 201 W. 4th St., #204, Claremont, CA 91711$4707)   
			
All reagents were purchased from Sigma$Aldrich Ltd. (Gillingham, Dorset, UK) unless 
otherwise stated. Assay buffer was 50 mM HEPES (pH 7.5), 50 mM NaCl and 1 mM CHAPS. 
Horseradish Peroxidase was initially diluted to 500 units/ml in water. 4$methyl$2$oxovalerate 
was initially diluted to 10 mM in assay buffer. L$Leucine and α$ketoglutarate were both initially 
diluted to 100 mM in 50 mM HEPES (pH 7.5) with pyridoxal phosphate (PLP) initially diluted 
to 10 mM in 50 mM HEPES (pH 7.5). Amplex red (Invitrogen, Paisley, UK) was initially diluted 
to 20 mM in DMSO. 
BCATm and L$GOX protein were cloned, expressed, and isolated in house (GSK, Stevenage, 
UK). The assay monitors the production of L$glutamate from branch chain amino$acids and α$
ketoglutarate through the coupling of hBCATm activity to two additional enzymes, L$Glutamate 
Oxidase (L$GOx) and Horseradish Peroxidase (HRP).  L$GOx catabolises L$glutamate to 
generate α$Ketoglutarate and hydrogen peroxide, the latter being utilised by HRP and leading to 
the formation of fluorescent resorufin from the redox sensitive dye Amplex Red.    
The BCATm fluorescent assay was carried out in low volume 384$well plates (Greiner Bio$
one, Stonehouse, UK) at a final volume of 10 bL per well. Test compounds were added to plates 
as 50 nL solutions in DMSO using an Echo 555 acoustic dispenser (Labcyte, Sunnyvale, CA) 
prior to the addition of assay components. Additionally, 50 nL DMSO or positive control (5$
chloro$2benzenzofurancaroxylic acid 2$[[2$(trifluromethyl)phenyl]sulfonyl] hydrazide; 
emolecules) was included in two columns each to give 100% activity and 100% inhibition 
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controls, respectively. Single$concentration testing was at 10 bM compound concentration. For 
pIC50 determination, compounds were tested using an 11$point, three$fold dilution series from 
either 625 bM or 6.25 bM prepared using a Biomek FX (Beckman Coulter, Wycombe, UK).  
To these compound plates, 4 bL of an enzyme$PLP solution containing 20 nM BCATm and 40 
nM PLP in assay buffer was added. Following this, 4 bL of a coupling solution containing 3 mM 
L$Leucine, 0.5 mM α$ketoglutarate, 10 units/mL HRP and 80 bM Amplex red in assay buffer 
was added to initiate the reaction. The coupling solution was incubated on a roller at room 
temperature in a 15 mL tube with 1 mL Agarose immobilised Catalase (Sigma$Aldrich Ltd.)  per 
10 mL of coupling solution to ‘scrub’ the coupling solution prior to addition of Amplex Red and 
remove background levels of hydrogen peroxide. After a 10 minute incubation, 2 bL of 100 mM 
4$methyl$2$oxovalerate was added to stop the reaction. 
Final assay concentrations were 10 nM BCATm, 20 nM PLP, 5 units per mL HRP, 1.5 mM L$
Leucine, 0.25 mM alpha$ketoglutarate and 40 bM Amplex Red. All additions were performed 
using a Multidrop Combi (Thermo Fisher Scientific, Waltham, MA). Plates were transferred to 
an EnVision reader (PerkinElmer) (excitation filter 525/20 nm; emission filter 598/25 nm).  
 
			
Differentiated primary human adipocytes (Zenbio) were challenged overnight using 
compounds dissolved in HBSS (Gibco 1g/L glucose) complemented with HEPES 10 mM, L$
Serine 50 µM and L$Leucine 150 µM.  Next day cell supernatant were subjected to amino acids 
determinations using HPLC analysis essentially as previously described.4  The method is based 
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on automated, online derivatization using o$phthalaldehyde (OPA) for primary amino acids and 
9$fluorenylmethyl chloroformate (FMOC) for secondary amino acids, using an Eclipse Plus C18 
3x10mm 3.5µm column to perform reversed phase HPLC (all chemicals and hardware from 
Agilent Technologies, Inc.). The percentage of inhibition was calculated on leucine 
concentration remaining compared to vehicle treated cells. 
		
FindAnalogues is an in$house developed PipelinePilot® [Pipeline Pilot (2010) Accelrys Ltd, 
San Diego] protocol developed to search for analogues of fragment compounds. The protocol 
used several search methods to retrieve analogues of fragment structures. The tautomers of the 
input molecule were enumerated prior to searching and core generation using the relevant 
PipelinePilot component. Tautomers were also enumerated for the core. A core was generated 
for each input query molecule by iteratively removing terminal chain atoms, stopping at O,N,S. 
An amide/sulfonamide/ester/acid was cleaved to leave either N or C=O/SO2. Additional rules 
break N$linked piperidines to leave N. Terminal Nitrogens are set to [#7]. [nH] to n. 
The core was used to conduct a substructure search on the relevant database. The JChem 
Cartridge was used for enabling chemical structure search and management within Oracle, 
JChem 5.3, ChemAxon (http://www.chemaxon.com). 
Similarity searches were performed on the database using the full query molecule and the 
ChemAxon fingerprint. Several similarity search metrics22 were used: Tversky searches23 using 
the input molecule as both the target and the query with alpha = 0.9, beta = 0.1, cut$off = 0.8; 
Tanimoto search with similarity cut$off of 0.8. Additionally a reduced graph24 substructure 
search  was performed with the reduced graph derived from the full query structure. Optionally, 
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limits could be placed on the hit list according to the difference in heavy atom count or 
molecular weight difference between the query and the hit molecule. This was particularly 
significant for the substructure and Tversky searches to control the size of the hit molecules. The 
total number of hits from any single query could also be specified, defined as MaxHits in the 
following.  For the SS and RG search, hits were ordered by molecular weight and the MaxHits 
lowest molecular weight compounds were returned. For the Tversky and Tanimoto search, the 
MaxHits most similar compounds were returned. 
4#				
%		
All NMR spectra were recorded in PBS buffer [pH7.2], 100% D2O, 300K and Bruker Avance 
700 MHz spectrometer, equipped with a 5mm cryo$probe and sample changer (Bruker$BioSpin). 
Sample volume was 180 µL in a 3mm sample tube (Norrell). A set of reference 1H NMR spectra 
for individual fragments was recorded in the absence of protein. 
Fragments were tested for binding to BCAT in pools of typically 5 compounds per sample at a 
concentration of 1 mM each. The protein concentration was 10 µM. Saturation of protein 1H 
resonances was achieved by continuous wave irradiation at 0.3 ppm for 2 s. A 30$ms spin$lock 
period was employed before acquisition to allow the residual protein signal to decay. STD 
spectra were processed and deconvoluted by comparison with the reference spectra of the 
individual compounds using the TOPSPIN program (Bruker BioSpin). Only STD signals to the 
left of the waterline (i.e. > 5.5ppm) were evaluated. The intensity of the largest resolved signal of 
each compound was determined and compared to the maximum noise level of the spectrum in 
the signal$free region between 11 and 12 ppm. STD signals with an intensity 4x above noise 
level were classified as hits. 
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			
The protein was diluted to a final concentration 2.4 µM in buffer (25 mM HEPES pH 7.5 
containing 25 mM NaCl, 20 mM DTT, 20 mM EDTA, 2.5 % glycerol). The PLP (E) form of the 
enzyme was prepared by incubation with a 100$fold excess of α$ketoglutarate for 1 minute at 20 
°C. The PMP (F) form of the enzyme was prepared by incubation with a 100$fold excess of l$
leucine for 1 minute at 20 °C. The isoforms of the enzyme were purified by centrifugal 
ultrafiltration at 15000 xg at 4 °C for 15 minutes using Vivaspin$6 10 kDa nominal molecular 
cut$off spin filters. The retentates were recovered and the volume adjusted to give a final protein 
concentration of  2.4 µM. The purified enzymes were stored at 4 °C until used. Samples were 
prepared in 96$well plates. 0.5 µL of buffer (control), DMSO or compound at 10 mM in DMSO 
were aliquoted into separate wells. To each well was added 50 µL of the required form of the 
enzyme containing a 1:1000 dilution of Sypro Orange (Invitrogen). The plate was incubated for 
1 min at room temperature and centrifuged for 1 minute at 1000 xg. 20 µL aliquots from each 
well were transferred to wells in sequential rows of a white 96$well plate (Abgene 0.2 mL semi$
skirted Thermo$Fast plate; AB$0900/w) and overlaid with 5 µL silicon oil. Data were acquired 
on an Exicycler rt$pcr instrument (Bioneer Inc). Fluorescence intensity was recorded at 0.5 °C 
intervals over a temperature range of 4 °C to 94 °C at a heating rate of 1 °C/min. The raw 
fluorescent intensity signals were exported into Excel csv format. The raw data were normalised 
using the formula: (cell value$MIN(column data range))/(MAX(column data range)$
MIN(column data range)) Where “cell value” is the raw fluorescence reading at each 
temperature point. 
The normalised fluorescence intensities versus temperature data were fitted to a standard 
denaturation isotherm in Grafit5  (Erithacus software). 
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?55	(	(			
	Human branched$chain amino acid aminotransferase mitochondrial (BCATm) (residues 28$
392) deleted of the N$terminal mitochondria signal peptide (residues 1$27) was cloned into 
Kanamycin resistant pET28a via NdeI/XhoI restriction endonuclease sites with an N$terminal 
6His$Thrombin cleavage site.  This was used to transform  :$	  BL21 Star (DE3) (Invitrogen) 
cells.  The transformed cells were grown in turbo media supplemented with glucose and 
kanamycin, after induction with IPTG 1mM the temperature was reduced from 37 oC to 25 oC 
and the cells harvested 23 hours later.  The human BCATm was purified using a modification of 
the method described by Conway and Huston25,  frozen cell pellets were thawed in buffer (25 
mM  HEPES, pH 7.5, 500 mM NaCl, 4 M Urea, 1 mM DTT, 20 mM Imidazole, Protease 
Inhibitor Cocktail III (MERCK) containing 0.1 mM Pyridoxal phosphate, 0.2 mg/ml lysozyme 
and 10 U/ml Benzonase (MERCK) and mixed for 30 minutes at room temperature.  The cell 
suspension was sonicated and the cell debris removed by centrifugation at 100,000 g for 90mins. 
The supernatant was loaded onto a 5 ml HisTrap HP column (GE Healthcare), washed with 10 
bed volumes (Bv) of buffer before running a gradient to 0 M Urea in buffer over 10 Bv at 5 
ml/min.  The column was eluted using a series of Imidazole steps 25, 50, 100, 200 and 500 mM 
in buffer (10 Bv of each at 5 ml/min).  The human BCATm containing fractions (100 mM & 200 
mM Imidazole step) were pooled and concentrated using  Amicon Ultra (Millipore) centrifugal 
ultrafilters with a 30 kDa (MWCO)and further purified using a Superdex200 column (GE 
Healthcare).  Dimeric human BCATm was pooled and buffer exchanged into thrombin cleavage 
buffer (50 mM HEPES, pH  7.5, 150 mM NaCl, 2 mM CaCl) and incubated for 2 hours at room 
temp with 10 U/ml of Thrombin (LeeBio).  After cleavage, DTT and (NH4)2SO4 was added at 1 
mM and 1.5 M, respectively and the thrombin removed by purification on a Butyl Sepharose HP 
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column (GE Healthcare). Human BCATm was eluted using a gradient to 0M (NH4)2SO4 over 20 
Bv.  The human BCATm was pooled, buffer exchanged into storage buffer (25 mM HEPES pH 
7.5, 25 mM NaCl, 20 mM DTT, 20 mM EDTA, 2.5 % glycerol), concentrated to ~10 mg/ml and 
snap frozen at $80 oC. Functional competency was confirmed using the coupled biochemical 
assay.  Structural integrity was confirmed using differential scanning fluorimetry measurements 
and protein crystalisation. 
The purified protein in 25 mM HEPES pH 7.5, 25 mM NaCl, 20 mM DTT, 20 mM EDTA, 2.5 
% glycerol and concentrated to at least 7.6 mg/mL was used for crystallography.    Crystals of 
BCATm were grown by hanging drop vapour diffusion at 20 °C with microseeding using MDL 
Morpheus™ screen condition B2 supplemented with 10 mM DTT in a protein to microseed 
solution of drop ratio of 1:1.  The Hampton Research seed$bead method was used to generate 
microseeds.  The crystals had a yellow hue suggestive of bound PLP cofactor despite none being 
added during purification or crystallization.  The complex with compound 27 was produced from 
a cocrystal grown under comparable conditions to the holoenzyme but in the presence of the 
compound (at 25 mM).	
+,	(	,				?55	(<	'	!  
Holocrystals were transferred to soaking buffer comprising MDL Morpheus™ screen 
condition B2 supplemented with 10 mM or 20 mM DTT and the compound of interest (from a 
stock solution dissolved in DMSO) at  the soaking concentration given in the X$ray summary 
table (in supplementary data).  Crystals were harvested in a cryo$loop and plunge$frozen into 
liquid nitrogen before loading in a puck for mounting with a sample collector.  Data from single 
crystals were collected at 100 K either at the Diamond Light Source (Harwell) or on an in$house 
Page 54 of 60
ACS Paragon Plus Environment
Journal of Medicinal Chemistry
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
 55
RIGAKU FR$E+ SUPERBRIGHT/Saturn A200 detector/ACTOR robotic system.  Data 
processing was achieve using DENZO26, MOSFLM27 or XDS28 (within AUTOPROC29)  and 
scaled using either SCALEPACK26 or SCALA30 within the CCP4 programming suite25.   
Structures were solved by Fourier synthesis using REFMAC32 (	 CCP4) starting from a 
previously determined in house structure, model$building was performed using COOT33 and 
refined using REFMAC 	 CCP4. The statistics for the data collection and refined co$ordinates 
are given in Supplementary information.  The final crystal structures are deposited in the Protein 
Data Bank under the accession codes 5I5S$Y and 5I60.  
((	 . Statistics for data collection and refined co$ordinates for X$ray 
crystallography are given in the supporting information. This material is available free of charge 
via the Internet at http://pubs.acs.org.  
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BCAT, branched$chain aminotransferase; BCAA, branched$chain amino acids; CLND, chemi$
luminescent nitrogen detection; FBDD, fragment based drug discovery; DIPEA, diisopropyl 
ethylamine; HATU, 1$[Bis(dimethylamino)methylene]$1$1,2,3$triazolo[4,5$+]pyridinium 3$
oxide hexafluorophosphate; HTS, high throughput screening; LE, ligand efficiency; LLEAT, 
lipophilic ligand efficiency defined by Astex; PK, pharmacokinetic; PLP pyridoxal phosphate; 
PMP, pyridoxamine phosphate; PPB, plasma protein binding; SAR, structure$activity 
relationship; STD$NMR, saturation$transfer difference nuclear magnetic resonance; Tm, thermal 
shift. 
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